WOBURN, Mass. , Aug. 04, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host investor meetings at